About

About Celaid Therapeutics Inc. Celaid Therapeutics Inc. is developing an allogeneic hematopoietic stem cell (HSC) therapy for hematological diseases in the United States, with both an IND filing and initiation of a Phase 1/2 clinical study planned for 2027. Originating from the University of Tokyo and the University of Tsukuba, Celaid is a biotechnology startup with proprietary technology for the selective ex vivo expansion of HSCs. By enabling safe, efficient, and scalable expansion of human HSCs, Celaid aims to advance next-generation cell and gene therapies, including treatments for hematologic and genetic diseases, ex vivo HSC gene therapies, and angiogenesis-based therapies for ischemic conditions. [Company's Conference Objectives] Celaid Therapeutics has two primary objectives: (1) to out-license its lead asset, CLD-001, to global pharma and biotech companies, and (2) to license its proprietary HSC expansion technology to CDMOs and pharma partners.______________________ (1) CLD-001 is an HSC therapy for non-malignant diseases (U.S. IND planned in 2027) that addresses key HSCT limitations—such as donor scarcity and HLA mismatch—by leveraging cord blood and proprietary expansion technology to deliver optimally matched, engraftable HSCs. (2) In parallel, Celaid is pursuing technology licensing and strategic collaborations, focusing on applications in iPSC-derived HSC expansion, ex vivo HSC gene therapy, and scalable manufacturing of blood and immune cell therapeutics, supported by joint research with global CDMO and pharma partners. [Lead asset pipeline, CLD-001] CLD-001 is being developed as a hematopoietic stem cell (HSC) therapy for hematological diseases, with an Investigational New Drug (IND) application planned in the United States in 2027. The program targets non-malignant diseases, addressing a significant unmet need in curative treatment options. Rare blood disorders - including aplastic anemia, primary immunodeficiencies, inherited metabolic disorders, and sickle cell disease - typically present in childhood and are associated with severe physical and neurological complications, leading to poor long-term prognosis. At present, the only curative treatment is allogeneic hematopoietic stem cell transplantation (HSCT). However, substantial limitations remain, including donor scarcity, HLA mismatch, transplant-related mortality, and complications such as graft-versus-host disease (GvHD). CLD-001 is designed to overcome these challenges. By utilizing cryopreserved cord blood from established cord blood banks, the therapy addresses donor availability constraints. Furthermore, proprietary HSC expansion technology resolves the inherent limitation of low stem cell counts in cord blood, enabling the generation of sufficient cell doses for transplantation. This approach allows for the selection and provision of optimally HLA-matched HSCs tailored to individual patients. Through these innovations, CLD-001 aims to deliver HLA best-matched, bone marrow–engrafting HSCs, with the potential to significantly improve engraftment outcomes and overall survival in patients undergoing HSC therapy. [Technology License activities] Celaid is also advancing technology license-out activities, positioning its platform for adoption by biotech companies, CDMOs, and pharmaceutical partners. Celaid has also been actively engaged in collaborative research with CDMOs and pharma companies across the U.S., Europe, and Japan, generating early commercial validation and demonstrating the platform’s ability to address partner-specific manufacturing challenges—particularly in iPSC-derived HSC expansion, ex vivo HSC gene therapy manufacturing, and the scalable production of blood and immune cell–based therapeutics.